IDEAYA Biosciences (IDYA) EBIT Margin (2020 - 2026)

IDEAYA Biosciences (IDYA) posted EBIT Margin of 1654.63% for Q1 2026, down 90.29% sequentially from 869.53% in Q4 2025.

IDEAYA Biosciences (IDYA) EBIT Margin (2020 - 2026) Analysis & Trends

IDEAYA Biosciences has reported EBIT Margin for 7 years, with the latest figure at 1654.63% in Q1 2026.

Quarterly EBIT Margin changed N/A year-over-year to 1654.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78.99% (changed N/A YoY) and the FY2025 annual result came in at 72.84%, up 459823.0% from the prior year.
EBIT Margin fell to 1654.63% in Q1 2026 per IDYA's latest filing, from 869.53% in the prior quarter.
Over five years, EBIT Margin peaked at 52.18% in Q3 2025 and troughed at 2059.11% in Q4 2024.
A 5-year average of 703.2% and a median of 537.28% in 2022 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2024 and 2025: EBIT Margin slumped 99035 bps in 2024, then jumped 118959 bps in 2025.
Over 5 years, EBIT Margin stood at 657.46% in 2022, then plunged by 63 bps to 1068.77% in 2023, then sank by 93 bps to 2059.11% in 2024, then surged by 58 bps to 869.53% in 2025, then slumped by 90 bps to 1654.63% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 1654.63%, 869.53%, and 52.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-105.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	IDEAYA Biosciences	3.50 Bn	2.67 Bn	-	-1,380.73%

Download Data